Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 12/20 | 0.37 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.37 |
| ▸ | PREP | P48147 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24593196 | 0.87 | HTR2A (0.43) | HTR2ASLC6A4KCNH2SLC5A2SLC5A1 | |
| SCHEMBL16871894 | 0.85 | PREP (0.39) | SLC5A2SLC5A1PREPCA12CA1 | |
| SCHEMBL1457146 | 0.85 | PREP (0.40) | SLC5A2SLC5A1PREPCA12CA1 | |
| SCHEMBL19303580 | 0.82 | HTR2A (0.43) | HTR2ASLC6A4KCNH2SLC5A2SLC5A1 | |
| SCHEMBL181109 | 0.80 | SLC5A2 (0.50) | HTR2ASLC6A4KCNH2SLC5A2SLC5A1 | |
| SCHEMBL30263682 | 0.80 | SLC5A2 (0.50) | HTR2ASLC6A4KCNH2SLC5A2SLC5A1 | |
| SCHEMBL462800 | 0.77 | SLC5A2 (0.37) | SLC5A2PREPCA12CA1CA9 | |
| SCHEMBL29041275 | 0.77 | PREP (0.36) | SLC5A2SLC5A1PREPCA12CA1 | |
| SCHEMBL38150 | 0.77 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL29386304 | 0.77 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3735975-B1 | ERTUGLIFLOZIN FOR USE IN TREATING HEART FAILURE IN PATIENTS WITH DIABETES | MERCK SHARP & DOHME LLC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12036203-B2 | Methods of treating or reducing the risk of cardiovascular events and related diseases using SGLT-2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-07-16 | — | — | US | disclosed |
| CN-108285439-B | Carbonoside sodium glucose transport protein body 2 inhibitor | 江苏天士力帝益药业有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-11548906-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | EMMENNAR PHARMA PRIVATE LIMITED (IN) | 2023-01-10 | — | — | US | disclosed |
| US-10913762-B2 | Process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl] oxy]phenyl] methyl] phenyl]-, (1S) and its crystalline forms thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2021-02-09 | — | — | US | disclosed |
| EP-3735975-A1 | METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND RELATED DISEASES USING SGLT-2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20200331946-A1 | PROCESSES FOR THE PREPARATION OF SGLT-2 INHIBITORS, INTERMEDIATES THEREOF | EMMENNAR PHARMA PRIVATE LIMITED, (IN) | 2020-10-22 | — | — | US | disclosed |
| US-20200297692-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | MERCK SHARP & DOHME CORP. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10709684-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | MERCK SHARP & DOHME CORP. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10703772-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | EMMENNAR PHARMA PRIVATE LIMITED (IN) | 2020-07-07 | — | — | US | disclosed |
| US-20060234953-A1 | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-19 | — | — | US | disclosed |
| WO-2006108842-A1 | GLUCOPYRANOSYL-SUBSTITUTED (HETEROARYLOXY-BENZYL)-BENZENE DERIVATIVES AS SGLT INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006089872-A1 | GLUCOPYRANOSYL-SUBSTITUTED ( (HETERO)ARYLETHYNYL-BENZYD-BENZENE DERIVATIVES AND USE THEREOF AS SODIUM-DEPENDENT GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-31 | — | — | WO | disclosed |
| US-20060189548-A1 | Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-24 | — | — | US | disclosed |
| US-20060142210-A1 | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| WO-2006064033-A2 | GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-22 | — | — | WO | disclosed |
| US-20060009400-A1 | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-12 | — | — | US | disclosed |
| WO-2006002912-A1 | D-XYLOPYRANOSYL-SUBSTITUTED PHENYLS, MEDICAMENTS CONTAINING SAID COMPOUNDS, THE USE THEREOF, AND METHODS FOR PRODUCING THE SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005092877-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-06 | — | — | WO | disclosed |
| US-20050209166-A1 | Metabolic disorders like diabetes; inhibits sodium-dependent glucose cotransporter; 1-chloro-2-(4-cyclopentyloxybenzyl)-4-( beta -D-glucopyranos-1-yl)-benzene | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297692-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | SLC5A1, SLC5A2, SLC2A1 | HTR2A 1723/4885SLC6A4 74/4885KCNH2 1345/4885 |
| US-20060189548-A1 | Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | UGGT1, UGT2B7, GPR119 | HTR2A 1233/4885SLC6A4 1076/4885KCNH2 1237/4885 |
| US-20050209166-A1 | Metabolic disorders like diabetes; inhibits sodium-dependent glucose cotransporter; 1-chloro-2-(4-cyclopentyloxybenzyl)-4-( beta -D-glucopyranos-1-yl)-benzene | SLC5A1, SLC5A2, SLC2A1 | HTR2A 2064/4885SLC6A4 37/4885KCNH2 344/4885 |
| US-10703772-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | SLC5A2, SLC5A1, SLC2A4 | HTR2A 2349/4885SLC6A4 65/4885KCNH2 1614/4885 |
| US-10709684-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | SLC5A1, SLC5A2, SLC2A1 | HTR2A 1723/4885SLC6A4 74/4885KCNH2 1345/4885 |
| US-20060009400-A1 | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | SLC5A1, SLC5A2, SLC2A1 | HTR2A 1459/4885SLC6A4 62/4885KCNH2 676/4885 |
| US-20060234953-A1 | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | UGGT1, UGT2B7, GYS2 | HTR2A 1997/4885SLC6A4 1397/4885KCNH2 1668/4885 |
| US-20060142210-A1 | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | UGGT1, SLC5A1, SLC5A2 | HTR2A 2688/4885SLC6A4 788/4885KCNH2 3250/4885 |
| US-11548906-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | SLC5A2, SLC5A1, SLC2A4 | HTR2A 2462/4885SLC6A4 101/4885KCNH2 1630/4885 |
| US-10913762-B2 | Process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl] oxy]phenyl] methyl] phenyl]-, (1S) and its crystalline forms thereof | ALG1, FBP1, DAD1 | HTR2A 4600/4885SLC6A4 4182/4885KCNH2 1884/4885 |
| US-20200331946-A1 | PROCESSES FOR THE PREPARATION OF SGLT-2 INHIBITORS, INTERMEDIATES THEREOF | SLC5A2, SLC5A1, SLC2A4 | HTR2A 2462/4885SLC6A4 101/4885KCNH2 1630/4885 |
| US-12036203-B2 | Methods of treating or reducing the risk of cardiovascular events and related diseases using SGLT-2 inhibitors | SLC5A1, SLC5A2, GLP1R | HTR2A 2800/4885SLC6A4 345/4885KCNH2 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.